Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening […]
RadNet, Inc. to Present at the Raymond James 45th Annual Institutional Investors Conference Today, March 4th, 2024
LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic […]
The Ensign Group Acquires Skilled Nursing Facility in Kansas
SAN JUAN CAPISTRANO, Calif., March 04, 2024 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the EnsignTM group […]
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused […]
Fusion Fuel Receives €1 Million Grant from European Innovation Fund for Alentejo Green Hydrogen Valley through H2tALENT Consortium
SABUGO, Portugal, March 04, 2024 (GLOBE NEWSWIRE) — Fusion Fuel (NASDAQ: HTOO) (the “Company”) announced today that it has received […]
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
– BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in […]
Andrew Fisher Joins Verona Pharma as General Counsel
LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), […]
BioVie Inc. Announces Pricing of Public Offering
CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company […]
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease VIVIAD Phase 2b study did […]
Coherus Completes Divestiture of Ophthalmology Franchise
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – […]
